Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic neuritis, according to a press release from Oculis.
If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies.
“We are excited to advance privosegtor in optic neuropathies to address the substantial unmet patient needs for neuroprotective therapies, with the potential to extend into retina and beyond,” Riad Sherif, MD, CEO of Oculis, told Healio.
The designation is supported by positive visual function results from the randomized,